Laboratory Interpretation and Management
Your labs show elevated ferritin (332 ng/mL) with high-normal transferrin saturation (44%) and normal iron studies, which suggests either early hemochromatosis, secondary iron overload, or inflammatory hyperferritinemia—you need HFE genetic testing to determine if this is hereditary hemochromatosis.
What These Labs Mean
Your iron panel reveals a specific pattern:
- Total iron: 131 mcg/dL (normal)
- TIBC: 298 mcg/dL (normal)
- Transferrin saturation: 44% (high-normal, just below the 45% threshold)
- Ferritin: 332 ng/mL (significantly elevated, >2x upper limit)
This pattern—normal iron parameters with elevated ferritin and borderline-high transferrin saturation—creates diagnostic uncertainty. According to the 2022 EASL guidelines, males with transferrin saturation >50% and ferritin >300 μg/L should undergo genetic testing for hemochromatosis 1. Your transferrin saturation of 44% falls just below this threshold, but your ferritin exceeds it.
Key Differential Diagnoses
Primary consideration: HFE-Hemochromatosis
- Even with "normal" transferrin saturation, iron overload can exist. Research demonstrates that 6.3% of confirmed C282Y homozygotes present with normal transferrin saturation (<50% in men) but elevated ferritin, and 75% of these patients had ≥3g iron removed by phlebotomy 2
- Critical finding: 5.2% of these patients had cirrhosis despite normal transferrin saturation 2
Secondary causes to exclude:
- Chronic inflammatory conditions (ferritin is an acute-phase reactant)
- Liver disease (hepatitis B/C, NAFLD, alcohol-related)
- Metabolic syndrome/dysmetabolic hyperferritinemia
- Hemolytic anemia
- Malignancy
Immediate Diagnostic Steps
1. Obtain HFE Genetic Testing (Priority Action)
You should proceed with genetic testing despite transferrin saturation <45% because:
- Your ferritin is significantly elevated (>300 μg/L in males per guidelines) 1
- Transferrin saturation at 44% is borderline and may fluctuate
- The 2022 EASL guidelines state that "otherwise unexplained persistently elevated transferrin saturation" warrants genetic testing with 100% consensus 1
- Test specifically for HFE p.C282Y mutation (most common in European ancestry)
2. Assess for Secondary Causes
Check the following labs:
- Liver function tests (AST, ALT) - elevated aminotransferases with ferritin >1000 μg/L predict cirrhosis 3
- CRP or ESR - to identify inflammatory conditions causing reactive hyperferritinemia
- Hepatitis B and C serologies
- Fasting glucose and lipid panel - dysmetabolic hyperferritinemia associates with metabolic syndrome 4
- Complete blood count - to exclude hemolysis
3. Clinical Assessment
Specifically evaluate for:
- Liver disease symptoms: hepatomegaly, stigmata of chronic liver disease
- Joint symptoms: arthritis, chondrocalcinosis (especially metacarpophalangeal joints)
- Endocrine dysfunction: diabetes, hypogonadism, hypothyroidism
- Cardiac symptoms: cardiomyopathy, heart failure
- Skin changes: hyperpigmentation
- Alcohol consumption: quantify intake precisely
- Family history: first-degree relatives with hemochromatosis or unexplained liver disease
Treatment Algorithm Based on Genetic Results
If C282Y Homozygous (or Compound Heterozygous C282Y/H63D with confirmed overload):
Initiate therapeutic phlebotomy 1:
- Induction phase: Remove 500 mL blood weekly until ferritin <50 μg/L
- Monitor hemoglobin before each session; discontinue if Hgb <11 g/dL
- Check ferritin monthly during induction
- Maintenance phase: Phlebotomy every 2-4 months to maintain ferritin 50-100 μg/L 1
Assess for advanced fibrosis/cirrhosis if:
- Ferritin >1000 μg/L with elevated liver enzymes 3
- Consider liver MRI to quantify hepatic iron concentration 1
- If cirrhosis present: enroll in hepatocellular carcinoma surveillance (ultrasound + AFP every 6 months)
If Non-C282Y Genotype or Negative Genetic Testing:
Focus on secondary causes:
- Treat underlying condition (metabolic syndrome, liver disease, inflammation)
- Do not perform phlebotomy unless confirmed iron overload on MRI (liver iron >35 μmol/g dry weight) 1
- Monitor ferritin and transferrin saturation every 3-6 months
- If ferritin remains stable or decreases, iron overload disease is unlikely 5
If Genetic Testing Shows C282Y/H63D Compound Heterozygosity or H63D Homozygosity:
Management guided by phenotype, not genotype alone 1:
- Investigate other causes of iron overload (93% consensus) 1
- Consider liver MRI to confirm iron overload
- Phlebotomy only if confirmed iron overload on imaging 1
Lifestyle Modifications (Regardless of Cause)
Dietary restrictions 1:
- Limit red meat consumption
- Avoid iron supplements and iron-fortified foods
- Avoid supplemental vitamin C (enhances iron absorption)
- Restrict alcohol: avoid completely if liver abnormalities present; limit to occasional small amounts otherwise
- Critical warning: Avoid raw/undercooked shellfish and seawater wound exposure—Vibrio vulnificus causes >50% mortality in iron overload patients 1
Monitoring Strategy
Until diagnosis clarified:
- Repeat transferrin saturation and ferritin in 3 months
- If transferrin saturation rises to ≥45%, this strengthens indication for genetic testing
- Persistently elevated transferrin saturation (even if <45%) warrants genetic evaluation 1
After treatment initiated:
- Hemoglobin before each phlebotomy session
- Ferritin monthly during induction, every 6 months during maintenance 1
- Monitor folate and B12 if numerous phlebotomies required 1
Critical Pitfalls to Avoid
Do not dismiss iron overload based on transferrin saturation <45%—research shows significant iron overload and even cirrhosis can occur with normal transferrin saturation 2
Do not assume elevated ferritin always means iron overload—40-70% of hyperferritinemia cases are multifactorial 5, but your borderline-high transferrin saturation makes true iron overload more likely
Do not over-phlebotomize—target ferritin 50-100 μg/L, not lower; iron deficiency can develop in hemochromatosis patients 1
Do not skip genetic testing—your ferritin >300 μg/L meets criteria even with transferrin saturation 44% given the clinical context 1
The emerging evidence suggests monitoring transferrin saturation during maintenance therapy may improve outcomes, as persistently elevated levels correlate with symptoms like fatigue and joint pain 6, though this remains an area of active investigation.